Loading
obrixtamig / Extensive Stage Small Cell Lung Cancer (ES SCLC) / Small Cell Lung Cancer (SCLC) · Phase 3 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized controlled trial registration comparing obrixtamig plus standard chemoimmunotherapy (atezolizumab, carboplatin, etoposide) versus standard treatment alone in adults with advanced small cell lung cancer. No results have been posted to the registry; the study is currently recruiting participants and outcomes will not be available for up to 3 years of follow-up.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC); age from 18 Years. Intervention: obrixtamig + atezolizumab, carboplatin, and etoposide treat…; atezolizumab, carboplatin, and etoposide control arm. Compared with: Atezolizumab, carboplatin, and etoposide (intravenous infusions) without obrixtamig.. n = 670. 244 sites across 42 countries.
This is a Phase 3 randomized controlled trial registration comparing obrixtamig plus standard chemoimmunotherapy (atezolizumab, carboplatin, etoposide) versus standard treatment alone in adults with advanced small cell lung cancer. No results have been posted to the registry; the study is currently recruiting participants and outcomes will not be available for up to 3 years of follow-up.
This is a registry record only; no efficacy, safety, or outcome data are reported.
The source did not state who this applies to in practice.
This is a Phase 3 RCT registration with no results posted; the study is actively recruiting and outcomes have not yet been reported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07472517). This is a study registration, not published results. Lead sponsor: Boehringer Ingelheim. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 670 participants (ESTIMATED). Conditions: Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC). Interventions: DRUG: obrixtamig; DRUG: atezolizumab; DRUG: carboplatin; DRUG: etoposide. Primary outcome measures: Overall survival (OS) , Up to 36 months. Brief summary: This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.